Aim: To investigate whether pentoxifylline (PTX) could influence the increased cytokine gene expression in the retina flowing transient ischemia, and if so, whether it acts through the modulation of nuclear factor kappa B (NF-ĸB) activation. Methods: Sprague-Dawley rats were randomly divided into three equal groups: control group, saline-treated group, and PTX-treated group. Increased intraocular pressure was applied for 90 min to induce retinal ischemia, and reperfusion was established by lowering the bottle to eye level. The reperfusion period lasted for 48 h. In the PTX-treated group, an initial dose of 20 mg PTX was injected via tail vein at the beginning of reperfusion. Then the rat received infusion of PTX at a rate of 6 mg/kg/h throughout the entire reperfusion period. The retinal tissues were collected at the end of 1, 6, 12, 24, and 48 h of reperfusion, respectively, for biochemical analysis. Histological examination was done on the tissues collected at the end of 48 h after reperfusion. Results: Histological examination revealed reduction of overall retinal thickness and thinning of the inner retinal layer in saline-treated rats after 48-hour reperfusion. However, PTX treatment significantly reduced the loss of overall retinal thickness and thinning of inner retinal layers. Dramatic increase in NF-ĸB activation, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) production and mRNA expression were observed in the saline-treated group after reperfusion, with the peak reached around 12 h. In the PTX-treated group, NF-ĸB activation, TNF-α and IL-1β production and mRNA expression were significantly reduced at each corresponding time point compared to the saline-treated group. Conclusion: PTX decreased the up-regulated activation of NF-ĸB and the expression of proinflammatory cytokines, TNF-α and IL-1β in rat retinas following ischemia/reperfusion. This may contribute to significantly reduce the loss of overall retinal thickness and thinning of inner retinal layers.

Keywords:
Pentoxifylline, Nuclear factor-ĸB, Tumor necrosis factor-α, Interleukin-1β, Retina, Ischemia/reperfusion, Rats
1.
Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J: Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 2004;23:91–147.
2.
Kristian T, Siesjo BK: Calcium in ischemic cell death. Stroke 1998;29:705–718.
3.
Lee JM, Zipfel GJ, Choi DW: The changing landscape of ischaemic brain injury mechanisms. Nature 1999;24:A7–A14.
4.
Lipton P: Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431–1568.
5.
Nishizawa Y: Glutamate release and neuronal damage in ischemia. Life Sci 2001;69:369–381.
6.
Demir T, Ulas F, Ozercan I, Ilhan N, Celiker U, Yasar MA: Protective effects of pentoxifylline in retinal ischemia/reperfusion injury. Ophthalmologica 2003;217:337–341.
7.
Kamphuis J, Smits P, Thien T: Vascular effects of pentoxifylline in humans. J Cardiovasc Pharmacol 1994;24:648–654.
8.
Nelson JL, Alexander JW, Mao JX, Vohs T, Ogle CK: Effect of pentoxifylline on survival and intestinal cytokine messenger RNA transcription in a rat model of ongoing peritoneal sepsis. Crit Care Med 1999;27:113–119.
9.
Incandela L, Cesarone MR, Belcaro G, Steigerwalt R, De Sanctis MT, Nicolaides AN, Griffin M, Geroulakos G, Ramaswami G: Treatment of vascular retinal disease with pentoxifylline: a controlled, randomized trial. Angiology 2002;53:S31–S34.
10.
Koo DJ, Yoo P, Cioffi WG, Bland KI, Chaudry IH, Wang P: Mechanism of the beneficial effects of pentoxifylline during sepsis: maintenance of adrenomedullin responsiveness and downregulation of proinflammatory cytokines. J Surg Res 2000;91:70–76.
11.
Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, Kunkel SL: Cellular and molecular regulation of TNF-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230–1236.
12.
Bienvenu J, Coulon L, Barbier Y, Doche C, Lepape A, Guenounou M: Study of pentoxifylline on TNF-α and interleukin-6 secretion in healthy and septic patients by the use of an ex-vivo model on whole blood. Nouv Rev Fr Hematol 1992;34(suppl):65–67.
13.
Weinberg JB, Mason SN, Wortham TS: Inhibition of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) messenger RNA (mRNA) expression in HL-60 leukemia cells by pentoxifylline and dexamethasone: dissociation of acivicin-induced TNF-α and IL-1β mRNA expression from acivicin-induced monocytoid differentiation. Blood 1992;79:3337–3343.
14.
Hangai M, Yoshimura N, Yoshida M, Yabuuchi K, Honda Y: Interleukin-1 gene expression in transient retinal ischemia in the rat. Invest Ophthalmol Vis Sci 1995;36:571–578.
15.
Hangai M, Yoshimura N, Honda Y: Increased cytokine gene expression in rat retina following transient ischemia. Ophthalmic Res 1996;28:248–254.
16.
Beutler B, Cerami A: The biology of cachectin/TNF-α primary mediator of the host response. Annu Rev Immunol 1989;7:625–655.
17.
Dinarello CA: Biology of interleukin 1. FASEB J 1988;2:108–115.
18.
Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649–683.
19.
Hughes WF: Quantitation of ischemic damage in the rat retina. Exp Eye Res 1991;53:573–582.
20.
Alagoz G, Celiker U, Ilhan N, Yekeler H, Demir T, Celiker H: L-Carnitine in experimental retinal ischemia-reperfusion injury. Ophthalmologica 2002;216:144–150.
21.
Roth S, Li B, Rosenbaum PS: Preconditioning provides complete protection against retinal ischemic injury in rats. Invest Ophthalmol Vis Sci 1998;39:777–785.
22.
Shimada T, Watanaba N, Ohtsuka Y, Endoh M, Kojima K, Hiraishi H, Terano A: Polaprezine downregulates proinflammatory cytokine-induced nuclear factor-κB activation and interleukin-8 expression in gastric epithelial cells. J Pharmacol Exp Ther 1999;291:345–352.
23.
Touzani O, Boutin H, Chuquet J, Rothwell N: Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J Neuroimmunol 1999;100:203–215.
24.
Patel HC, Boutin H, Allan SM: Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann NY Acad Sci 2003;992:39–47.
25.
Wang CX, Shuaib A: Involvement of inflammatory cytokines in central nervous system injury. Prog Neurobiol 2002;67:161–172.
26.
Hallenbeck JM: The many faces of tumor necrosis factor in stroke. Nat Med 2002;8:1363–1368.
27.
Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U: Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002;22:RC216. Epub 2002 Mar 25.
28.
Tezel G, Wax MB: Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci 2000;20:8693–8700.
29.
Tanihara H, Yoshida M, Yoshimura N: Tumor necrosis factor-alpha gene is expressed in stimulated retinal pigment epithelial cells in culture. Biochem Biophys Res Commun 1992;187:1029–1034.
30.
Limb GA, Little BC, Meager A, Ogilvie JA, Wolstencroft RA, Franks WA, Chignell AH, Dumonde DC: Cytokines in proliferative vitreoretinopathy. Eye1991;5:686–693.
31.
Yoneda S, Tanihara H, Kido N, Honda Y, Goto W, Hara H, Miyawaki N: Interleukin-1beta mediates ischemic injury in the rat retina. Exp Eye Res 2001;73:661–667.
32.
Mizushima H, Zhou CJ, Dohi K, Horai R, Asano M, Iwakura Y, Hirabayashi T, Arata S, Nakajo S, Takaki A, Ohtaki H, Shioda S: Reduced postischemic apoptosis in the hippocampus of mice deficient in interleukin-1. J Comp Neurol 2002;448:203–216.
33.
Ohtaki H, Takaki A, Yin L, Dohi K, Nakamachi T, Matsunaga M, Horai R, Asano M, Iwakura Y, Shioda S: Suppression of oxidative stress after transient focal ischemia in interleukin-1 knock out mice. Acta Neurochir Suppl 2003;86:191–194.
34.
Beg AA, Finco PV, Nantermet TS, Baldwin AS Jr: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol 1993;13:3301–3310.
35.
Baeuerle PA, Baltimore D: NF-kappa B: ten years after. Cell 1996;87:13–20.
36.
Blackwell TS, Christman JW: The role of nuclear factor kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17:3–9.
37.
Benveniste EN: Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol 1992;263:C1–C16.
38.
Dauber IM, Lesnefsky EJ, Ashmore RC, Martel DM, Sheridan FM, Weil JV, Horwitz LD: Coronary vascular injury due to ischemia-reperfusion is reduced by pentoxifylline. J Pharmacol Exp Ther 1992;260:1250–1256.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.